Medical marijuana for inflammatory bowel disease: the highs and lows

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi:
   PubMed Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel J-F, et al. Crohn’s disease. Lancet. 2017;389(10080):1741–1755.
   PubMed Web of Science ®Google Scholar
• Costa Santos M, Gomes C, Torres J. Familial and ethnic risk in inflammatory bowel disease. Ann Gastroenterol. 2018;31(1):14–23.
   PubMed Web of Science ®Google Scholar
• Swaminath A, Berlin EP, Cheifetz A, et al. The role of cannabis in the management of inflammatory bowel disease: a review of clinical, scientific, and regulatory information. Inflamm Bowel Dis. 2019;25(3):427–435.
   PubMed Web of Science ®Google Scholar
• Ng S, Shi H, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778.
   PubMed Web of Science ®Google Scholar
• Shivashankar R, Tremaine WJ, Harmsen WS, et al. Incidence and prevalence of crohn’s disease and ulcerative colitis in olmsted county, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol. 2017;15(6):857–863.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Love B. Management of patients with inflammatory bowel disease: current and future treatments. Pharm J. 2017.DOI:https://doi.org/10.1211/CP.2017.20202316.
   Google Scholar
• Weisshof R, Jurdi K, Zmeter N, et al. Emerging therapies for inflammatory bowel disease. Adv Ther. 2018;35(11):1746–1762.
   PubMed Web of Science ®Google Scholar
• Rubin D. 2020. Multinational inflammatory bowel disease survey uncovers striking differences in patients’ and physicians’ treatment goals and disease management expectations. https://news.bms.com/press-release/corporatefinancial-news/multinational-inflammatory-bowel-disease-survey-uncovers-strik.
   Google Scholar
• Basson AR, Lam M, Cominelli F. Complementary and alternative medicine strategies for therapeutic gut microbiota modulation in inflammatory bowel disease and their next-generation approaches. Gastroenterol Clin North Am. 2017;46(4):689–729.
   PubMed Web of Science ®Google Scholar
• Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23(10):891–896.
   PubMed Web of Science ®Google Scholar
• Lafaye G, Karila L, Blecha L, et al. Cannabis, cannabinoids, and health. Dialogues Clin Neurosci. 2017;19(3):309–316.
   PubMed Web of Science ®Google Scholar
• Madras K. Update of cannabis and its medical use. Geneva, Switzerland: World Health Organisation Expert Committee on Drug Dependence; 2015.
   Google Scholar
• National Conference of State Legislatures. 2021. State medical marijuana laws. https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx.
   Google Scholar
• Gotfried J, Naftali T, Schey R. Role of cannabis and its derivatives in gastrointestinal and hepatic disease. Gastroenterology. 2020;159(1):62–80.
   PubMed Web of Science ®Google Scholar
• Alhouayek M, Muccioli GG. The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med. 2012;18(10):615–625.
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes. 2006;30(S1):S13–S18.
   Google Scholar
• Leinwand KL, Gerich ME, Hoffenberg EJ, et al. Manipulation of the endocannabinoid system in colitis: a comprehensive review. Inflamm Bowel Dis. 2017;23(2):192–199.
   PubMed Web of Science ®Google Scholar
• Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010;126(1):21–38.
   PubMed Web of Science ®Google Scholar
• Duncan M, Davison JS, Sharkey KA. Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther. 2005;22(8):667–683.
   PubMed Web of Science ®Google Scholar
• Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008;153(2):263–270.
   PubMed Web of Science ®Google Scholar
• Kunos G. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am J Med. 2007;120(9):18–24.
   Web of Science ®Google Scholar
• Matias I, Marzo VD. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab. 2007;18(1):27–37.
   PubMed Web of Science ®Google Scholar
• Marzo VD. CB1 receptor antagonism: biological basis for metabolic effects. Drug Discov Today. 2008;13(23-24):1026–1041.
   PubMed Web of Science ®Google Scholar
• Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323(7303):16–21.
   PubMed Web of Science ®Google Scholar
• Sickle MDV, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310(5746):329–332.
   PubMed Web of Science ®Google Scholar
• Slatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol. 2007;5(5 Suppl 3):1–9.
   PubMedGoogle Scholar
• Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut. 2008;57(8):1140–1155.
   PubMed Web of Science ®Google Scholar
• Marzo VD, Izzo AA. Endocannabinoid overactivity and intestinal inflammation. Gut. 2006;55(10):1373–1376.
   PubMed Web of Science ®Google Scholar
• Smid SD. Gastrointestinal endocannabinoid system: multifaceted roles in the healthy and inflamed intestine. Clin Exp Pharmacol Physiol. 2008;35(11):1383–1387.
   PubMed Web of Science ®Google Scholar
• Sabatino AD, Battista N, Biancheri P, et al. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. Mucosal Immunol. 2011;4(5):574–583.
   PubMed Web of Science ®Google Scholar
• Couch DG, Maudslay H, Doleman B, et al. The use of cannabinoids in colitis: a systematic review and meta-analysis. Inflamm Bowel Dis. 2018;24(4):680–697.
   PubMed Web of Science ®Google Scholar
• Ahmed W, Katz S. Therapeutic use of cannabis in inflammatory bowel disease. Gastroenterol Hepatol. 2016;12(11):668–679.
   Google Scholar
• Katchan V, David P, Shoenfeld Y. Cannabinoids and autoimmune diseases: a systematic review. Autoimmun Rev. 2016;15(6):513–528.
   PubMed Web of Science ®Google Scholar
• Lin SC, Cheifetz AS. The use of complementary and alternative medicine in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2018;14(7):415–425.
   PubMedGoogle Scholar
• Substance Abuse and Mental Health Services Administration. 2019. 2018 National Survey on Drug Use and Health. Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/.
   Google Scholar
• Allegretti JR, Courtwright A, Lucci M, et al. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(13):2809–2814.
   PubMed Web of Science ®Google Scholar
• Benson MJ, Abelev SV, Connor SJ, et al. Medicinal cannabis for inflammatory bowel disease: a survey of perspectives, experiences, and current use in Australian patients. Crohns Colitis. 2020;360:2.
   Google Scholar
• Weiss A, Friedenberg F. Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend. 2015;156:84–89.
   PubMed Web of Science ®Google Scholar
• Russell C, Rueda S, Room R, et al. Routes of administration for cannabis use - basic prevalence and related health outcomes: A scoping review and synthesis. Int J Drug Policy. 2018;52:87–96.
   PubMed Web of Science ®Google Scholar
• Schauer GL, King BA, Bunnell RE, et al. Toking, vaping, and eating for health or fun: marijuana use patterns in adults, U.S., 2014. Am J Prev Med. 2016;50(1):1–8.
   PubMed Web of Science ®Google Scholar
• Azorlosa JL, Greenwald MK, Stitzer ML. Marijuana smoking: effects of varying puff volume and breathhold duration. J Pharmacol Exp Ther. 1995;272(2):560–569.
   PubMed Web of Science ®Google Scholar
• Azorlosa JL, Heishman SJ, Stitzer ML, et al. Marijuana smoking: effect of varying Delta 9-tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther. 1992;261(1):114–122.
   PubMed Web of Science ®Google Scholar
• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327–360.
   PubMed Web of Science ®Google Scholar
• Naftali T, Lev LB, Yablecovitch D, et al. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J. 2011;13(8):455–458.
   PubMed Web of Science ®Google Scholar
• Naftali T, Schleider LBL, Dotan I, et al. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11(10):1276–1280.e1.
   PubMed Web of Science ®Google Scholar
• Naftali T, Mechulam R, Marii A, et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn’s Disease, a Randomized Controlled Trial. Dig Dis Sci. 2017;62(6):1615–1620.
   PubMed Web of Science ®Google Scholar
• Naftali T, Schleider LBL, Benjaminov FS, et al. Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects. Eur J Gastroenterol Hepatol. 2019;31(11):1.
   PubMed Web of Science ®Google Scholar
• Lahat A, Lang A, Ben-Horin S. Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion. 2012;85(1):1–8.
   PubMed Web of Science ®Google Scholar
• Irving PM, Iqbal T, Nwokolo C, et al. A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis. 2018;24(4):714–724.
   PubMed Web of Science ®Google Scholar
• Naftali T, Schleider LBL, Benjaminov FS, et al. Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: a randomized controlled trial. PLoS One. 2021;16(2):e0246871.
   PubMed Web of Science ®Google Scholar
• Naftali T, Bar-Lev Schleider L, Almog S, et al. Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn’s disease, a randomized controlled trial. J Crohn’s Colitis. 2021;24(4):jjab069. DOI:https://doi.org/10.1093/ecco-jcc/jjab069.
   Google Scholar
• Harvey RF, Bradshaw JM. A simple index of crohn’s-disease activity. Lancet. 1980;1(8167):514.
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, et al. Development of a crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70(3):439–444.
   PubMed Web of Science ®Google Scholar
• Thia K, Faubion WA, Loftus EV, et al. Short CDAI: development and validation of a shortened and simplified crohnʼs disease activity index. Inflamm Bowel Dis. 2011;17(1):105–111.
   PubMed Web of Science ®Google Scholar
• Lahiff C, Safaie P, Awais A, et al. The Crohn’s disease activity index (CDAI) is similarly elevated in patients with Crohn’s disease and in patients with irritable bowel. Aliment Pharmacol Ther. 2013;37(8):786–794.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, c-reactive protein normalisation and mucosal healing in Crohns disease in the SONIC trial. Gut. 2014;63(1):88–95.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Mao R, Chen M. Optimizing biologic treatment in IBD: objective measures, but when, how and how often? BMC Gastroenterol. 2015;15:178.
   PubMed Web of Science ®Google Scholar
• Docherty MJ, Jones RCW, Wallace MS. Managing pain in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011;7(9):592–601.
   PubMedGoogle Scholar
• Berry SK, Takakura W, Bresee C, et al. Pain in inflammatory bowel disease is not improved during hospitalization: the impact of opioids on pain and healthcare utilization. Dig Dis Sci. 2020;65(6):1777–1783.
   PubMed Web of Science ®Google Scholar
• Szigethy E, Knisely M, Drossman D. Opioid misuse in gastroenterology and non-opioid management of abdominal pain. Nat Rev Gastroenterol Hepatol. 2018;15(3):168–180.
   PubMed Web of Science ®Google Scholar
• Zielińska A, Sałaga M, Włodarczyk M, et al. Focus on current and future management possibilities in inflammatory bowel disease-related chronic pain. Int J Colorectal Dis. 2019;34(2):217–227.
   PubMed Web of Science ®Google Scholar
• Burr NE, Smith C, West R, et al. Increasing prescription of opiates and mortality in patients with inflammatory bowel diseases in England. Clin Gastroenterol Hepatol. 2018;16(4):534–541.
   PubMed Web of Science ®Google Scholar
• Targownik LE, Nugent Z, Singh H, et al. The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis. Am J Gastroenterol. 2014;109(10):1613–1620.
   PubMed Web of Science ®Google Scholar
• Noureldin M, Higgins PDR, Govani SM, et al. Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids. Aliment Pharmacol Ther. 2019;49(1):74–83.
   PubMed Web of Science ®Google Scholar
• Dalal RS, Palchaudhuri S, Snider CK, et al. Exposure to intravenous opioids is associated with future exposure to opioids in hospitalized patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;18(10):2269–2278.
   PubMed Web of Science ®Google Scholar
• Choung RS, Locke GR, Zinsmeister AR, et al. Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study. Am J Gastroenterol. 2009;104(5):1199–1204.
   PubMed Web of Science ®Google Scholar
• Tuteja AK, Biskupiak J, Stoddard GJ, et al. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil. 2010;22(4):424–430, e96.
   PubMed Web of Science ®Google Scholar
• Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7(5):R1046–R1051.
   PubMed Web of Science ®Google Scholar
• Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011;171(7):686–691.
   PubMed Web of Science ®Google Scholar
• Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63(7):649–671.
   PubMed Web of Science ®Google Scholar
• Mehendale SR, Yuan CS. Opioid-induced gastrointestinal dysfunction. Dig Dis. 2006;24(1–2):105–112.
   PubMed Web of Science ®Google Scholar
• Hanson KA, Loftus EV, Harmsen SW, et al. Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a case–control study. Inflamm Bowel Dis. 2009;15(5):772–777.
   PubMed Web of Science ®Google Scholar
• Grunkemeier DM, Cassara JE, Dalton CB, et al. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol. 2007;5(10):1126–1139.
   PubMed Web of Science ®Google Scholar
• Marijuana Policy Project. 2021. Map of State Marijuana Laws [Digital image]. https://www.mpp.org/issues/legalization/map-of-state-marijuana-laws/.
   Google Scholar
• Russo E. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2008;4(1):245–259.
   PubMedGoogle Scholar
• Wen H, Hockenberry JM. Association of medical and adult-use marijuana laws with opioid prescribing for medicaid enrollees. JAMA Intern Med. 2018;178(5):673–679.
   PubMed Web of Science ®Google Scholar
• Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in medicare part D. Health Aff (Millwood). 2016;35(7):1230–1236.
   PubMed Web of Science ®Google Scholar
• Ishida JH, Wong PO, Cohen BE, et al. Substitution of marijuana for opioids in a national survey of US adults. PloS One. 2019;14(10):e0222577.
   PubMed Web of Science ®Google Scholar
• Shah A, Hayes CJ, Lakkad M, et al. Impact of medical marijuana legalization on opioid use, chronic opioid use, and high-risk opioid use. J Gen Intern Med. 2019;34(8):1419–1426.
   PubMed Web of Science ®Google Scholar
• Shi Y. Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend. 2017;173:144–150.
   PubMed Web of Science ®Google Scholar
• Livingston MD, Barnett TE, Delcher C, et al. Recreational cannabis legalization and opioid-related deaths in Colorado, 2000–2015. Am J Public Health. 2017;107(11):1827–1829.
   PubMed Web of Science ®Google Scholar
• Dalal R, Palchaudhuri S, Snider CK, et al. Preadmission cannabis use is positively correlated with inpatient opioid dose exposure in hospitalized patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2021;27(4):500–506.
   PubMed Web of Science ®Google Scholar
• Bostwick JM. Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc. 2012;87(2):172–186.
   PubMed Web of Science ®Google Scholar
• Johns A. Psychiatric effects of cannabis. Br J Psychiatry. 2001;178(2):116–122.
   PubMedGoogle Scholar
• Lopez-Quintero C, Cobos JPDL, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the national epidemiologic survey on alcohol and related conditions (NESARC). Drug Alcohol Depend. 2011;115(1–2):120–130.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Baler RD, Compton WM, et al. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219–2227.
   PubMed Web of Science ®Google Scholar
• Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry. 2006;19(3):233–238.
   PubMed Web of Science ®Google Scholar
• Solowij N, Pesa N, Castle D, et al. Cannabis and cognition: short and long-term effects, marijuana and madness. 2nd ed. Cambridge: Cambridge University Press; 2012. p. 91–102.
   Google Scholar
• Lenné MG, Dietze PM, Triggs TJ, et al. The effects of cannabis and alcohol on simulated arterial driving: influences of driving experience and task demand. Accid Anal Prev. 2010;42(3):859–866.
   PubMed Web of Science ®Google Scholar
• Drummer OH, Gerostamoulos J, Batziris H, et al. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prev. 2004;36(2):239–248.
   PubMed Web of Science ®Google Scholar
• Laumon B, Gadegbeku B, Martin JL, et al. Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ. 2005;331(7529):1371.
   PubMedGoogle Scholar
• Hall W, Pacula RL. 2003. Cannabis use and dependence: public health and public policy. New York: Cambridge University Press.
   Google Scholar
• Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698):1383–1391.
   PubMed Web of Science ®Google Scholar
• Andrade LF, Carroll KM, Petry NM. Marijuana use is associated with risky sexual behaviors in treatment-seeking polysubstance abusers. Am J Drug Alcohol Abuse. 2013;39(4):266–271.
   PubMed Web of Science ®Google Scholar
• Lane SD, Cherek DR, Tcheremissine OV, et al. Acute marijuana effects on human risk taking. Neuropsychopharmacology. 2005;30(4):800–809.
   PubMed Web of Science ®Google Scholar
• Clayton HB, Lowry R, Ashley C, et al. Health risk behaviors with synthetic cannabinoids versus marijuana. Pediatrics. 2017;139(4). DOI:https://doi.org/10.1542/peds.2016-2675.
   Google Scholar
• Macleod J, Oakes R, Copello A, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet. 2004;363(9421):1579–1588.
   PubMed Web of Science ®Google Scholar
• Taylor DR, Fergusson DM, Milne BJ, et al. A longitudinal study of the effects of tobacco and cannabis exposure on lung function in young adults. Addiction. 2002;97(8):1055–1061.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Baldwin GC, Sarafian T, et al. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol. 2002;42(S1):71–81.
   Google Scholar
• Tetrault JM, Crothers K, Moore BA, et al. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med. 2007;167(3):221–228.
   PubMedGoogle Scholar
• Forti MD, Sallis H, Allegri F, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40(6):1509–1517.
   PubMed Web of Science ®Google Scholar
• Zammit S, Alleback P, Andreasson S, et al. Self reported cannabis use as a risk factor for schizophrenia in swedish conscripts of 1969: historical cohort study. BMJ. 2002;325(7374):1199–1199.
   PubMed Web of Science ®Google Scholar
• Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-o-methyltransferase gene: longitudinal evidence of a gene x environment interaction. Biol Psychiatry. 2005;57(10):1117–1127.
   PubMed Web of Science ®Google Scholar
• Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805–2809.
   PubMed Web of Science ®Google Scholar
• Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol. 2014;113(1):187–190.
   PubMed Web of Science ®Google Scholar
• Mukamal KJ, Maclure M, Muller JE, et al. An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. Am Heart J. 2008;155(3):465–470.
   PubMed Web of Science ®Google Scholar
• Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev. 2011;4(4):241–249.
   PubMedGoogle Scholar
• Pergolizzi J, LeQuang J, Bisney J. Cannabinoid hyperemesis. Med Cannabis Cannabinoids. 2019;1(2):73–95.
   PubMedGoogle Scholar
• Habboushe J, Rubin A, Liu H, et al. The prevalence of cannabinoid hyperemesis syndrome among regular marijuana smokers in an urban public hospital. Basic Clin Pharmacol Toxicol. 2018;122(6):660–662.
   PubMed Web of Science ®Google Scholar
• Grant I, Gonzalez R, Carey CL, et al. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc. 2003;9(5):679–689.
   PubMed Web of Science ®Google Scholar
• Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol. 2012;20(5):420–429.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73(3):292–297.
   PubMed Web of Science ®Google Scholar
• Lubman DI, Cheetham A, Yücel M. Cannabis and adolescent brain development. Pharmacol Ther. 2015;148:1–16.
   PubMed Web of Science ®Google Scholar
• Fontes MA, Bolla KI, Cunha PJ, et al. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry. 2011;198(6):442–447.
   PubMed Web of Science ®Google Scholar
• Gruber SA, Sagar KA, Dahlgren MK, et al. Age of onset of marijuana use and executive function. Psychol Addict Behav. 2012;26(3):496–506.
   PubMed Web of Science ®Google Scholar
• Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA. 2012;109(40):2657–2664.
   PubMed Web of Science ®Google Scholar